Monday’s Midday Stock Update: Cytokinetics (CYTK), Amarin (AMRN), Clovis Oncology (CLVS), SunPower (SPWR), Tesla (TSLA)

By Carrie Williams

So far Monday, December 16, NASDAQ is up 1.07% and the S&P is up 0.86%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Cytokinetics (CYTKResearch Report), Amarin (AMRNResearch Report), Clovis Oncology (CLVSResearch Report), SunPower (SPWRResearch Report) and Tesla (TSLAResearch Report).

Cytokinetics is down -8.91% in midday trading to $10.02. Shares opened today at $11.00. The company has a 52-week low of $5.75 and a 52-week high of $14.94. On the Street’s front, the average 12-month analyst price target for the stock is $27.00, marking a 145.45% potential upside from current levels. In a report issued on November 19, H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on CYTK, with a price target of $30.00, which represents a potential upside of 173% from where the stock is currently trading. In the last 30 days, insiders purchased $3.23M worth of CYTK shares. Over the last 3 months, the insider sentiment on Cytokinetics has been positive based on 24 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

Amarin is down -8.08% in midday trading to $23.45. Shares opened today at $25.51. The company has a 52-week low of $11.78 and a 52-week high of $26.12. On the Street’s front, the average 12-month analyst price target for the stock is $28.11, marking a 10.19% potential upside from current levels. In a report released today, Stifel Nicolaus analyst Derek Archila downgraded AMRN to Hold, with a price target of $28.00, which implies an upside of 10% from current levels. Separately, on the same day, Cantor Fitzgerald’s Louise Chen maintained a Buy rating on the stock and has a price target of $35.00. Over the last 3 months, the insider sentiment on Amarin has been positive based on 64 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

Clovis Oncology is down -7.26% in midday trading to $12.13. Shares opened today at $13.08. The company has a 52-week low of $2.93 and a 52-week high of $32.05. On the Street’s front, the average 12-month analyst price target for the stock is $11.42, marking a -12.69% potential downside from current levels. In a report issued on November 19, Evercore ISI analyst Joshua Schimmer downgraded CLVS to Hold, with a price target of $8.00, which implies a downside of 39% from current levels. Separately, on November 8, H.C. Wainwright’s Edward White reiterated a Buy rating on the stock and has a price target of $36.00. In the last 30 days, insiders purchased $34.55K worth of CLVS shares.

See today’s analyst top recommended stocks >>

SunPower is up 6.2% in midday trading to $8.22. Shares opened today at $7.74. The company has a 52-week low of $4.55 and a 52-week high of $16.04. On the Street’s front, the average 12-month analyst price target for the stock is $9.54, marking a 23.26% potential upside from current levels. In a report released today, Morgan Stanley analyst Stephen Byrd maintained a Sell rating on SPWR, with a price target of $5.80, which represents a potential downside of 25% from where the stock is currently trading. Separately, on November 22, Cowen’s Jeff Osborne maintained a Buy rating on the stock and has a price target of $9.50. In the last 30 days, insiders purchased $206.7K worth of SPWR shares.

See today’s analyst top recommended stocks >>

Tesla is up 5.3% in midday trading to $381.77. Shares opened today at $362.55. The company has a 52-week low of $176.99 and a 52-week high of $383.46. On the Street’s front, the average 12-month analyst price target for the stock is $286.06, marking a -21.10% potential downside from current levels. In a report issued on December 13, Deutsche Bank analyst Emmanuel Rosner maintained a Hold rating on TSLA. Separately, on December 10, Robert W. Baird’s Ben Kallo reiterated a Buy rating on the stock and has a price target of $355.00. In the last 30 days, insiders have sold $5.73M worth of TSLA shares. Over the last 3 months, the insider sentiment on Tesla has been negative based on 54 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Trending Stocks Based on Insider Activity >>